New Drugs for Acute Heart Failure

Authors

  • Mohammad Salman Department of Cardiology, Anwer Khan Modern Medical College, Dhanmondi, Dhaka
  • Syed Allahsan Department of Cardiology, Bangabandhu Sheikh Mujib Medical University, Dhaka
  • Manzoor Mahmood Department of Cardiology, Bangabandhu Sheikh Mujib Medical University, Dhaka
  • Md Khairul Anam Department of Cardiology, Bangabandhu Sheikh Mujib Medical University, Dhaka
  • Shahed Mohammad Anwar University of Science and Technology, Chittagong
  • Roksana Afrose Chittagong Ma O Shishu and General Hospital, Chittagong
  • Md Abu Afrose Department of Cardiology, Bangabandhu Sheikh Mujib Medical University, Dhaka
  • Md Ashraf Uddin Sultan Department of Cardiology, Bangabandhu Sheikh Mujib Medical University, Dhaka
  • Fazlur Rahman Department of Cardiology, Bangabandhu Sheikh Mujib Medical University, Dhaka

DOI:

https://doi.org/10.3329/uhj.v7i1.10208

Keywords:

Acute heart failure, Nesiritide, Levosimendan.

Abstract

Acute heart failure is a major health problem responsible for several million hospitalizations worldwide each year. Standard therapy has not changed for long time and includes diuretics and variable use of vasodilators or inotropes. Recently Nesiritide and Levosimendan are two drugs for the treatment of acute heart failure which have been approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMEA), respectively. There was little concern that Nesiritide can worsen the renal failure but recent trials had abolished this concern.

DOI: http://dx.doi.org/10.3329/uhj.v7i1.10208

UHJ 2011; 7(1): 35-38

Downloads

Download data is not yet available.
Abstract
90
PDF
79

Downloads

Published

2012-03-29

How to Cite

Salman, M., Allahsan, S., Mahmood, M., Anam, M. K., Anwar, S. M., Afrose, R., Afrose, M. A., Uddin Sultan, M. A., & Rahman, F. (2012). New Drugs for Acute Heart Failure. University Heart Journal, 7(1), 35–38. https://doi.org/10.3329/uhj.v7i1.10208

Issue

Vol. 7 No. 1 (2011)

Section

Review Articles

License

Authors are required to transfer their copyright to the University Heart Journal.